Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Only women of non-child bearing potential are included in the study i.e. women who are permanently or surgically sterilised or post menopausal.
≥ 40 years of age at Visit 1
Clinical diagnosis of COPD (GOLD stage 1)
FEV1 ≥ 80% of the predicted normal post-bronchodilator at Visit 1 (GOLD stage 1)
FEV1/FVC \<70% post-bronchodilator at Visit 1 (GOLD stage 1)
You may not be if
Any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk or influence the way the drug works
Any clinically relevant abnormal findings in physical examination, blood or urine test results, vital signs or ECG at Visit 1 that may put the subject at risk during the study, affect their ability or take part or influence the results of the study
A past history or current indication of renal (kidney) failure
Subjects at risk of active tuberculosis or of disease reactivation
Subjects who have had any clinically significant illness within 4 weeks before Visit 2 (start of treatment)
Clareo Health | Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)
